Treatment · July 2, 2026
First Module of Rolling FDA Application Submitted for Rare Skin Condition Drug
Palvella Therapeutics advances toward FDA approval for QTORIN™, a potential new treatment for microcystic lymphatic malformations....
Treatment · June 16, 2026
FDA Accepts New Drug Application for Liquid Form of Seizure Medication
FDA accepts a new drug application for cenobamate oral suspension, advancing seizure disorder treatment....